Meeting
2019 Gastrointestinal Cancers Symposium
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
Authors
T.R. Jeffry Evans
University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
T.R. Jeffry Evans , Sarah Patricia Blagden , Janet Shirley Graham , Kristen Keon Ciombor , Aimery De Gramont , Josep Tabernero , Jordan Berlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT03428958
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS719)
DOI
10.1200/JCO.2019.37.4_suppl.TPS719
Abstract #
TPS719
Poster Bd #
Q4
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.
First Author: Sarah Patricia Blagden
Poster
2021 Gastrointestinal Cancers Symposium
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).
First Author: Andrew L. Coveler
Poster
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
First Author: Hasan Nadeem
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando